Osteoporosis News and Research

Latest Osteoporosis News and Research

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Merck (Merck is known as MSD outside the United States and Canada) today announced a strategic collaboration between MSD South Africa and Adcock Ingram, a publicly held South African company, to co-promote and distribute a number of established MSD products in South Africa. The products that will be jointly promoted by MSD and Adcock Ingram include over-the-counter (OTC) products and selected prescription medicines currently registered in South Africa by MSD and Schering-Plough.

24 Jun 2010

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Researchers at UT Southwestern Medical Center have pinpointed a set of biological mechanisms through which estrogen confers its beneficial effects on the cardiovascular system, independent of the hormone's actions on cancer. Their investigation suggests that drugs targeting a specific subpopulation of estrogen receptors found outside the cell nucleus might activate the cardiovascular benefits of estrogen without increasing cancer risk.

24 Jun 2010

Pfizer announces suspension of osteoarthritis clinical program for tanezumab

Pfizer Inc. announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration. The worldwide suspension – which is effective immediately – follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement.

24 Jun 2010

KYPHON ActivOs 10 Bone Cement with HA launched to treat patients with VCFs

Medtronic, Inc. today announced the launch of KYPHON ActivOs 10 Bone Cement with Hydroxyapatite, a polymethylmethacrylate bone cement containing hydroxyapatite for use in the treatment of patients with vertebral compression fractures who are undergoing minimally invasive surgery with KYPHON Balloon Kyphoplasty.

22 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

Research findings support the need to establish standards for DFSA care

New toxicology findings reveal the presence of drugs and/or alcohol in 76 per cent of women and men who suspect they were victims of drug-facilitated sexual assault. Of those, 64 per cent did not report voluntarily consuming the drugs found, supporting their belief that they may have been slipped a drug. In addition, unexpected male DNA was found in a substantial number of cases, confirming sexual activity.

19 Jun 2010

Childrens Hospital Los Angeles awarded $2.5M NIH grant to study risk of osteoporosis in spina bifida children

Tishya Wren, PhD, of The Saban Research Institute at Childrens Hospital Los Angeles, has received a $2.5 million grant from the National Institutes of Health - National Institute of Child Health and Human Development to study bone development in children with myelomeningocele, the most severe type of spina bifida .

19 Jun 2010

Tongjitang first-quarter net revenue up 25.6% to $16.6 million

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended March 31, 2010.

19 Jun 2010

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

The non-profit Inamori Foundation (President: Dr. Kazuo Inamori) today announced that Dr. Shinya Yamanaka will receive its 26th annual Kyoto Prize in Advanced Technology, which for 2010 focuses on the fields of Biotechnology and Medical Technology. Dr. Yamanaka, 47, will receive the award for his pioneering work in developing a technology to generate pluripotent stem cells that does not require the use of human embryos.

18 Jun 2010

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

Two separate studies have shown that vitamin D deficiency is common in patients with a range of rheumatic diseases, with over half of all patients having below the 'normal' healthy levels of vitamin D (48-145 nmol/L) in their bodies. A further study assessing response to vitamin D supplementation found that taking the recommended daily dose did not normalise vitamin D levels in rheumatic disease patients.

18 Jun 2010

Postmenopausal women who have low calcium intake show higher risk of developing osteoporosis, hypertension

Italian postmenopausal women who have a low calcium intake show a higher risk of developing both osteoporosis and hypertension (a chronic medical condition in which arterial blood pressure is elevated) than those who consume higher levels of calcium according to research presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Vitamin D may help reduce the incidence and severity of viral respiratory tract infections including influenza, according to a new study conducted by investigators at Greenwich Hospital and Yale University School of Medicine.

16 Jun 2010

Female endurance sports athletes are at risk for serious health issues, say physicians

Female endurance sports athletes may be at risk for serious health issues, according to physicians at Loyola University Health System. Excessive exercise and inadequate nutrition can lead to problems such as low energy, menstrual irregularity, fertility issues, stress fractures and osteoporosis.

15 Jun 2010

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

14 Jun 2010

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Further results from the European Survey of Breakthrough Cancer Pain were presented for the first time today at the 6th Research Congress of the European Association for Palliative Care in Glasgow.

11 Jun 2010

Misinterpretation of genetic information may undermine efforts to promote behavioral changes for disease prevention

Does knowing that genes are partly responsible for your health condition mean you are less likely to be motivated to find out about the benefits of behavioral changes? According to Dr. Suzanne O'Neill from the National Human Genome Research Institute/National Institutes of Health, and her colleagues, people on the whole are still interested in how health habits affect disease risk.

10 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

SciMed Technologies receives certification for VitaKit A from AOAC International

SciMed Technologies Inc. today announces they received certification from the AOAC International - a worldwide scientific association dedicated to analytical excellence - for VitaKit A the world's first 2 hour rapid test for accurate analysis of vitamin A in liquid milk.

8 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The data, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.

7 Jun 2010

Osteoporosis News and Research

Latest Osteoporosis News and Research

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Pfizer announces suspension of osteoarthritis clinical program for tanezumab

KYPHON ActivOs 10 Bone Cement with HA launched to treat patients with VCFs

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Research findings support the need to establish standards for DFSA care

Childrens Hospital Los Angeles awarded $2.5M NIH grant to study risk of osteoporosis in spina bifida children

Tongjitang first-quarter net revenue up 25.6% to $16.6 million

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

Postmenopausal women who have low calcium intake show higher risk of developing osteoporosis, hypertension

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Female endurance sports athletes are at risk for serious health issues, say physicians

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Misinterpretation of genetic information may undermine efforts to promote behavioral changes for disease prevention

Some commonly used drugs cause bone loss: New research

SciMed Technologies receives certification for VitaKit A from AOAC International

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Osteoporosis News and Research

Latest Osteoporosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in